^
    Back
    Association details:
    Biomarker:KRAS G12C
    Cancer:Non Small Cell Lung Cancer
    Drug:Xpovio (selinexor) (XPO1 inhibitor) +
    MRTX1257 (KRAS inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Cancer Res Commun
    Title:

    Inhibitor of the Nuclear Transport Protein XPO1 Enhances the Anticancer Efficacy of KRAS G12C Inhibitors in Preclinical Models of KRAS G12C–Mutant Cancers

    Published date:
    05/10/2022
    Excerpt:
    KRAS G12C–mutant NCI-H2122, NCI-H358 (NSCLC) and MiaPaCa-2 (PDAC) cells were subjected to in vitro MRTX1257 and selinexor treatments at different dose combinations....all three dose combinations tested demonstrated synergistic inhibition of NCI-H2122 and NCI-H358 cell proliferation (CI value < 1).
    DOI:
    https://doi.org/10.1158/2767-9764.CRC-21-0176
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    AACR 2021
    Title:

    1058 - Inhibition of nuclear transport protein XPO1 potentiates the effect of KRAS G12C inhibitors

    Published date:
    03/10/2021
    Excerpt:
    MRTX1257 and AMG510, when combined with KPT-330, synergistically inhibited (Combination Index values less than 1) the proliferation of KRASG12C mutant cancer cell lines, namely MiaPaCa-2 (PDAC) and NCI-H2122 (NSCLC).